On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases

On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases

In patients with inflammatory bowel diseases (IBD) undergoing biologic therapy, biomarkers of treatment response are still scarce. This study aimed to evaluate whether serum zonulin, a biomarker of intestinal permeability; soluble CD163 (sCD163), a macrophage activation marker; and a panel of serum...

Full description

Bibliographic Details
Main Authors: Gian Paolo Caviglia, Chiara Rosso, Francesco Stalla, Martina Rizzo, Alessandro Massano, Maria Lorena Abate, Antonella Olivero, Angelo Armandi, Ester Vanni, Ramy Younes, Sharmila Fagoonee, Rinaldo Pellicano, Marco Astegiano, Giorgio Maria Saracco, Elisabetta Bugianesi, Davide Giuseppe Ribaldone
Format: Article
Language:English
Published: MDPI AG 2020-03-01
Series:Journal of Clinical Medicine
Subjects:
adalimumab
crohn’s disease
cytokines
il-6
scd163
ulcerative colitis
ustekinumab
vedolizumab
zonulin
Online Access:https://www.mdpi.com/2077-0383/9/3/800

Internet

https://www.mdpi.com/2077-0383/9/3/800

Similar Items